Websites
- www.fda.gov/oc/initiatives/criticalpath/whitepaper.pdf Innovation or Stagnation? Challenge and Opportunity on the Critical Path to New Medical Products. Department of Health and Human Services. Food and Drug Administration (FDA), March 2004.
- www.fda.gov/cder/guidance/6400fnl.pdf Guidance for Industry: Pharmacogenomic Data Submissions. US Department of Health and Human Services, Food and Drug Administration, March 2005
- www.fda.gov/cder/genomics/VGDS.htm Overall VGDS process.
- www.fda.gov/cder/genomics/pharmacoconceptfn.pdf~ Drug-Diagnostic Co-Development Concept Paper (Draft). Department of Health and Human Services (HHS), Food and Drug Administration (FDA) April 2005
- www.cioms.ch/frame_pharmacogenetics_febr_2005.htm Pharmacogenetics. Towards improving treatment with medicines. ISBN 92 9036 078 X.
- www.fda.gov/cber/gdlns/iche14QTc.pdf The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrythmic Potential for Non-Antiarrhythmic Drugs
- www.nuffieldbioethics.org/fileLibrary/pdf/pharmacogenetics_report.pdf Pharmacogenetics: Ethical Issues. Nuffield Council on Bioethics, September 2003.